High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Derr, Remco S ^a   van Hoesel, Anneke Q ^a   Benard, Anne ^a   Goossens Beumer, Inès J ^a   Sajet, Anita ^a   Dekker Ensink, N Geeske ^a   de Kruijf, Esther M ^a   Bastiaannet, Esther ^a   Smit, Vincent T H B M ^a   van de Velde, Cornelis J H ^a   Kuppen, Peter J K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Breast cancer; Clinical outcome; Epigenetics; HDAC2; Histone modifying enzymes; LSD1; SIRT1

Indexed keywords

HISTONE; HISTONE DEACETYLASE 2; LSD 1 PROTEIN; PROTEIN; SIRTUIN 1; UNCLASSIFIED DRUG; HDAC2 PROTEIN, HUMAN; HISTONE DEMETHYLASE; KDM1A PROTEIN, HUMAN; SIRT1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ANALYSIS; EPIGENETICS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATHOGENESIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; TISSUE MICROARRAY; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; VERY ELDERLY; BREAST TUMOR; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 2; HISTONE DEMETHYLASES; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SIRTUIN 1; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84906837824     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-604     Document Type: Review

References (27)

1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144. 10.1093/annonc/mdm271, 17675394.
2. Marme F, Schneeweiss A. Personalized therapy in breast cancer. Onkologie 2012, 35(Suppl 1):28-33.
3. Nowsheen S, Aziz K, Tran PT, Gorgoulis VG, Yang ES, Georgakilas AG. Epigenetic inactivation of DNA repair in breast cancer. Cancer Lett 2012, 342:213-222.
4. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 2007, 8:307-318. 10.1038/nrm2143, 17342184.
5. Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R. Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol 2012, 12:13. 10.1186/1472-6890-12-13, 3511290, 22920283.
6. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432. 10.1038/sj.onc.1210610, 17694083.
7. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011, 104:1828-1835. 10.1038/bjc.2011.156, 3111195, 21559012.
8. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009, 69:1702-1705. 10.1158/0008-5472.CAN-08-3365, 19244112.
9. Sung JY, Kim R, Kim JE, Lee J. Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 2010, 101:1738-1744. 10.1111/j.1349-7006.2010.01573.x, 20412117.
10. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS, Jang KY. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011, 42:204-213. 10.1016/j.humpath.2010.05.023, 21056897.
11. Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat 2012, 131:777-789. 10.1007/s10549-011-1480-8, 3624096, 21452019.
12. Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis 2013, 34:1196-1207. 10.1093/carcin/bgt033, 3670252, 23354309.
13. Mulligan P, Yang F, Di SL, Ji JY, Ouyang J, Nishikawa JL, Toiber D, Kulkarni M, Wang Q, Najafi-Shoushtari SH, Mostoslavsky R, Gygi SP, Gill G, Dyson NJ, Naar AM. A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. Mol Cell 2011, 42:689-699. 10.1016/j.molcel.2011.04.020, 3119599, 21596603.
14. de Kruijf EM, Engels CC, van de Water W, Bastiaannet E, Smit VT, van de Velde CJ, Liefers GJ, Kuppen PJ. Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. Breast Cancer Res Treat 2013, 142:355-364. 10.1007/s10549-013-2752-2, 24197659.
15. Federation of Medical Scientific Societies Code for Proper Secondary Use of Human Tissue in the Netherlands. 43. http://www.federa.org/sites/default/files/bijlagen/coreon/codepropersecondaryuseofhumantissue1_0.pdf, Federation of Medical Scientific Societies.
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005, 93:387-391. 10.1038/sj.bjc.6602678, 2361579, 16106245.
17. Gu H, Roizman B. Engagement of the lysine-specific demethylase/HDAC1/CoREST/REST complex by herpes simplex virus 1. J Virol 2009, 83:4376-4385. 10.1128/JVI.02515-08, 2668468, 19193804.
18. Lin Y, Wu Y, Li J, Dong C, Ye X, Chi YI, Evers BM, Zhou BP. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J 2010, 29:1803-1816. 10.1038/emboj.2010.63, 2885925, 20389281.
19. Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J, Nicosia SV, Zhang X. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 2009, 28:445-460. 10.1038/onc.2008.388, 18850005.
20. van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, Smit VT, Kay C, van de Vijver MJ, Kuppen PJ, Bartlett JM. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 2011, 125:671-685. 10.1007/s10549-010-0854-7, 20358279.
21. Engels CC, Ruberta F, de Kruijf EM, van Pelt GW, Smit VT, Liefers GJ, Matsushima T, Shibayama M, Ishihara H, van de Velde CJ, Kuppen PJ. The prognostic value of apoptotic and proliferative markers in breast cancer. Breast Cancer Res Treat 2013, 142:323-339. 10.1007/s10549-013-2748-y, 24194179.
22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
23. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011, 128:574-586. 10.1002/ijc.25349, 20333681.
24. Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denckert C. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 2013, 13:215. 10.1186/1471-2407-13-215, 3646665, 23627572.
25. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekattar R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by the lysine demethylase LSD1. Nature 2007, 449:105-108. 10.1038/nature06092, 17805299.
26. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123:437-448. 10.1016/j.cell.2005.08.011, 16269335.
27. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007, 67:3145-3152. 10.1158/0008-5472.CAN-06-4397, 17409421.